Treatment-Resistant Depression (TRD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034
Treatment-Resistant Depression (TRD) Emerging Therapy and TPP Insights Thelansis’s “Treatment-Resistant Depression (TRD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Treatment-Resistant Depression (TRD) Overview Treatment-Resistant Depression (TRD) is a challenging subtype of major depressive disorder in which patients fail to respond adequately to at least two different antidepressants given at proper doses and durations, often leaving them with persistent symptoms such as low mood, fatigue, sleep disturbances, and cognitive impairment. The condition affects nearly a third of individuals with depression and may be influenced by genetic factors, comorbid psychiatric or medical conditions, and poor medicati...